What is filgotinib?

Filgotinib (Filgotinib), a Janus kinase inhibitor, is used to treat rheumatoid arthritis and ulcerative colitis (UC) cases that are refractory to conventional treatments. It is selective for the JAK1 subtype of the enzyme. It is considered a promising drug because it selectively inhibits JAK1, similar to the already marketed upadatinib, which has shown long-term efficacy in treating various inflammatory diseases.

Signaling of a large number of pro-inflammatory cytokines is dependent onJAK1. Inhibiting JAK2 may also help combat rheumatoid arthritis. Nonetheless, JAK2 inhibition may lead to anemia and thrombocytopenia by interfering with erythropoietin, thrombopoietin, and granulocyte-macrophage colony-stimulating factor. It may therefore be preferable to choose more selective JAK1 inhibitors as the primary treatment option. Filgotinib is 30 times more selective for JAK1 than JAK2. However, it remains to be seen to what extent JAK2 inhibition should be avoided. However, their lack of selectivity results in dose-limiting side effects. Most believe that inhibition of allJAK isoenzymes is beneficial for rheumatoid arthritis. However, pan-JAK inhibition may also cause unwanted side effects that may not outweigh its benefits.

The original drug filgotinib has not yet been launched in China, and therefore is not included in medical insurance. The Bangladeshi version of the filgotinitine generic drug currently on the market overseas, specifications100mg*30 tablets may cost more than 500 yuan per box (the price may fluctuate due to exchange rates), and its drug ingredients are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.